Transformation from lung adenocarcinoma to combined small cell carcinoma in pleural effusion after treatment with osimertinib

The transformation of lung adenocarcinoma to combined small cell lung cancer is a rare mechanism of acquired resistance to EGFR tyrosine kinase inhibitors. This case describes this mechanism in a pleural effusion of a young patient treated with osimertinib for 18 months.

Detalles Bibliográficos
Autores principales: Frankel, Diane, Kaspi, Elise, Liprandi, Agnès, Dales, Jean‐Philippe, Roll, Patrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544831/
https://www.ncbi.nlm.nih.gov/pubmed/35689552
http://dx.doi.org/10.1111/cyt.13156
_version_ 1784804686390362112
author Frankel, Diane
Kaspi, Elise
Liprandi, Agnès
Dales, Jean‐Philippe
Roll, Patrice
author_facet Frankel, Diane
Kaspi, Elise
Liprandi, Agnès
Dales, Jean‐Philippe
Roll, Patrice
author_sort Frankel, Diane
collection PubMed
description The transformation of lung adenocarcinoma to combined small cell lung cancer is a rare mechanism of acquired resistance to EGFR tyrosine kinase inhibitors. This case describes this mechanism in a pleural effusion of a young patient treated with osimertinib for 18 months.
format Online
Article
Text
id pubmed-9544831
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95448312022-10-14 Transformation from lung adenocarcinoma to combined small cell carcinoma in pleural effusion after treatment with osimertinib Frankel, Diane Kaspi, Elise Liprandi, Agnès Dales, Jean‐Philippe Roll, Patrice Cytopathology Case Reports The transformation of lung adenocarcinoma to combined small cell lung cancer is a rare mechanism of acquired resistance to EGFR tyrosine kinase inhibitors. This case describes this mechanism in a pleural effusion of a young patient treated with osimertinib for 18 months. John Wiley and Sons Inc. 2022-06-24 2022-09 /pmc/articles/PMC9544831/ /pubmed/35689552 http://dx.doi.org/10.1111/cyt.13156 Text en © 2022 The Authors. Cytopathology published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Frankel, Diane
Kaspi, Elise
Liprandi, Agnès
Dales, Jean‐Philippe
Roll, Patrice
Transformation from lung adenocarcinoma to combined small cell carcinoma in pleural effusion after treatment with osimertinib
title Transformation from lung adenocarcinoma to combined small cell carcinoma in pleural effusion after treatment with osimertinib
title_full Transformation from lung adenocarcinoma to combined small cell carcinoma in pleural effusion after treatment with osimertinib
title_fullStr Transformation from lung adenocarcinoma to combined small cell carcinoma in pleural effusion after treatment with osimertinib
title_full_unstemmed Transformation from lung adenocarcinoma to combined small cell carcinoma in pleural effusion after treatment with osimertinib
title_short Transformation from lung adenocarcinoma to combined small cell carcinoma in pleural effusion after treatment with osimertinib
title_sort transformation from lung adenocarcinoma to combined small cell carcinoma in pleural effusion after treatment with osimertinib
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544831/
https://www.ncbi.nlm.nih.gov/pubmed/35689552
http://dx.doi.org/10.1111/cyt.13156
work_keys_str_mv AT frankeldiane transformationfromlungadenocarcinomatocombinedsmallcellcarcinomainpleuraleffusionaftertreatmentwithosimertinib
AT kaspielise transformationfromlungadenocarcinomatocombinedsmallcellcarcinomainpleuraleffusionaftertreatmentwithosimertinib
AT liprandiagnes transformationfromlungadenocarcinomatocombinedsmallcellcarcinomainpleuraleffusionaftertreatmentwithosimertinib
AT dalesjeanphilippe transformationfromlungadenocarcinomatocombinedsmallcellcarcinomainpleuraleffusionaftertreatmentwithosimertinib
AT rollpatrice transformationfromlungadenocarcinomatocombinedsmallcellcarcinomainpleuraleffusionaftertreatmentwithosimertinib

Ejemplares similares